People

Mateu-Gelabert-276x303
Pedro Mateu-Gelabert, PhD
CUNY Graduate School of Public Health and Health Policy - Associate Professor
Education
PhD, Sociology, New York University
BA, Sociology, Universidad Complutense, Madrid
Research Interests
Epidemiology of drug use, HIV/HCV prevention, Prescription opioid misuse, Overdose, HIV in Latin America, Urban ethnography
BIO
Pedro Mateu-Gelabert is an Associate Professor at the CUNY Graduate School of Public Health and Health Policy and a sociologist with over 20 years of research experience in New York City and internationally. His research spans the epidemiology of drug use, urban studies, crime, immigration, social networks, and HIV/Hepatitis C prevention. He has more than 50 peer-reviewed publications and has been guest lecturer in numerous national and international forums including University of Chicago, Columbia University, Beth Israel Medical Center, Colombian Ministry of Health, Rio de Janeiro Office of Public Safety, and Office of Human Rights in San José (Costa Rica). Dr. Mateu-Gelabert has collaborated with various interdisciplinary research teams, including the New York City Department of Health and Mental Hygiene (NYCDOHMH), Weill Cornell Medical College, and Beth Israel Medical Center. He has worked on international projects in multiple countries including Colombia (Emerging heroin markets leading to HIV epidemics among young injectors), Spain (HCV prevention among injection drug users) and Ukraine (HIV treatment access and care cascade for people who inject drugs).
Projects
Principal Investigator, Accessible Care Intervention for Engaging People Who Inject Illicit Drugs (PWID) in Hepatitis C Care. Active
Principal Investigator, Staying Safe Intervention: Preventing HCV Among Youth Opioid Injectors. Active
Principal Investigator, HIV, HCV and STI Risk Associated with Nonmedical Use of Prescription Opioids. Completed
Principal Investigator, Staying Safe: Training IDUs in Strategies to Avoid HIV and HCV Infection. Completed
Publications

Recent

Kapadia SN, Eckhardt BJ, Leff JA, Fong C, Mateu-Gelabert P, Marks KM, Aponte-Melendez Y, Schackman BR (2022).
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial
Drug and Alcohol Dependence Reports, 5, 100109. doi: 10.1016/j.dadr.2022.100109.

Hrycko A, Mateu-Gelabert P, Ciervo C, Linn-Walton R, Eckhardt B (2022).
Factors associated with severe bacterial infections in people who inject drugs: A single-center observational study
Journal of Addiction Medicine [Epub 2022 Oct 18]. doi: 10.1097/ADM.0000000000001099.

Eckhardt B, Aponte-Melendez Y, Kapadia SN, Mateu-Gelabert P (2022).
Contact tracing in acute hepatitis C: The source patient identification and group overlap therapy proof-of-concept pilot program
Clinical Liver Disease, 20 (2), 72-76. doi: 10.1002/cld.1242. PMCID: PMC9405500.

Mateu-Gelabert P, Sabounchi NS, Guarino H, Ciervo C, Joseph K, Eckhardt BJ, Fong C, Kapadia SN, Huang TTK (2022).
Hepatitis C virus risk among young people who inject drugs
Frontiers in Public Health, 10, 835836. doi: 10.3389/fpubh.2022.835836. PMCID: PMC9372473.

Eckhardt B, Kapadia SN, Mateu-Gelabert P, Pai M, Fong C, Aponte-Melendez Y, Marks KM (2022).
Rapid treatment initiation for hepatitis C in young people who inject drugs: The seek, test, and rapid treatment randomized trial
Open Forum Infectious Diseases, 9 (7), ofac225. doi: 10.1093/ofid/ofac225. PMCID: PMC9272437.

Dr. Mateu-Gelabert's Google Scholar Profile
Selected Press